SEC Form 4	
------------	--

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549													OMB APPROVAL					
Section 16. Form 4 or Form 5 obligations may continue. See							AT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person <sup>*</sup> <u>Reich Samuel J</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SAB Biotherapeutics</u> , Inc. [ SABS ]							ck all applica Director	ole)	10		% Owner	
(Last) (First) (Middle)   2100 E 54TH STREET NORTH						3. Date of Earliest Transaction (Month/Day/Year) 11/17/2021							Officer (g below) E		e Chai	Other (specify below) Chairman		
(Street) SIOUX FALLS SD 57104					4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)																	
1. Title of Security (Instr. 3) 2. Transa Date				ansacti	Tivative Securities Ac nsaction th/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		d Date,	3. Transactio Code (Instr	4. Securit Disposed	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		or 5. Amount o		Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Amount	(A) or (D)	Price	Transactio (Instr. 3 an				(1150.4)		
			Table II -						iired, Disp options,				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A) (D) Date Expiration Date Title		Amount or Number of Shares	- Transa (Instr. 4		ction(s) 4)						

Explanation of Responses:

\$11.17

Employee Stock Option

(right to buy)

1. Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

Α

2. The shares underlying the option vest over a three-year period, vesting 1/3 on the one-year anniversary of the date of grant, and the remaining 2/3 vesting pro rata on a monthly basis in 24 equal installments thereafter.

(2)

/s/ Samuel J. Reich

Common

Stock

11/17/2031

\*\* Signature of Reporting Person Date

350,000

\$0.00

350,000

11/19/2021

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

11/17/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

350,000<sup>(1)</sup>